Biocryst Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biocryst (US): 2 reconciled FDA prescription therapies, $131.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$131.0M
2024 Medicare Part D Spend$77.9M
2024 Medicaid Spend$53.1M
California HCAI SB 17 Filings2 WAC filings (max 20.2% 2-yr change)